# PT-141 Research: The RECONNECT Trials, the Mechanism, and the Evidence > PT-141 (bremelanotide) research: the RECONNECT Phase 3 trials in premenopausal women with HSDD, the central MC4R mechanism, the fMRI data, and the off-label male evidence — every quantitative claim cited. The melanocortin mechanism, the two RECONNECT Phase 3 trials, the neuroimaging evidence, and an honest reading of how large the approved-population effect actually is. ## The short version PT-141 (bremelanotide) was tested heavily before approval. Two large twin trials called RECONNECT studied it in premenopausal women with HSDD (hypoactive sexual desire disorder — distressing low sexual desire), and both hit their main goals: desire went up and the distress went down, compared with placebo [3]. The honest catch is that the size of the improvement was real but modest, and independent reviewers have argued about how meaningful it is in everyday terms [3]. Separate, much earlier work in men with erectile problems showed the molecule could act, but that line of research never reached approval. Below, each finding is tied to its study. ## What is a melanocortin receptor agonist? PT-141 is a melanocortin receptor agonist — it switches on melanocortin receptors, chiefly the central MC4R (with secondary MC3R action) [1]. The earliest pharmacology established the through-line: as a synthetic alpha-MSH analogue, systemic PT-141 produced penile erections in rats and nonhuman primates and activated hypothalamic neurons (seen as increased c-Fos, a marker of nerve-cell activity), pointing to a central rather than peripheral mechanism [1]. The same early program reported rapid, dose-dependent erectile activity in men with erectile dysfunction — the first signal of the off-label male story [1]. The mechanism is the spine of everything that follows: PT-141 acts on the brain's desire circuitry, not on the vasculature. ## How the central mechanism was confirmed The female-desire mechanism was nailed down in stages. In female rats, PT-141 selectively increased appetitive, solicitational sexual behaviors — the proceptive, desire-driven kind — without changing lordosis, pacing, or general movement, making it the first pharmacological agent shown to act on appetitive female sexual behavior [2]. That selectivity mattered: it showed the central melanocortin system regulates sexual desire specifically, not motor activity generally. The human mechanistic capstone came in 2022. In a randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli — enhancing amygdala-insula functional connectivity and cerebellar and supplementary-motor activity [5]. This is direct neuroimaging evidence that activating MC4R changes how the brain handles sexual cues. ## The RECONNECT Phase 3 trials Approval rested on RECONNECT: two identical Phase 3 randomized controlled trials (studies 301 and 302) in 1,267 premenopausal women with HSDD [3]. Participants self-administered bremelanotide 1.75 mg subcutaneously as needed. Both trials met their coprimary endpoints over 24 weeks: the integrated improvement in the FSFI desire-domain score (FSFI is the Female Sexual Function Index, a standard questionnaire that scores sexual desire) was +0.35 versus placebo (P<.001), and the integrated reduction in desire-related distress on FSDS-DAO item 13 (FSDS-DAO is the companion questionnaire that scores the distress low desire causes) was -0.33 versus placebo (P<.001) [3]. A 52-week open-label extension followed 684 women. No new safety signals emerged, and the desire improvements were sustained over long-term use [4]. The most common drug-related adverse events in that extension were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. A patient-experience analysis added the human layer, describing how treated women perceived the benefit and tolerability against those trial-measured effect sizes [3]. ## What PT-141 was shown to do in trials The PT-141 benefits supported by the trials are specific and bounded: in premenopausal women with HSDD, an as-needed 1.75 mg subcutaneous dose produced a statistically significant rise in sexual desire and a statistically significant drop in the distress that low desire caused, sustained across a year of open-label use [3][4]. Both coprimary endpoints were met in both pivotal trials — a reproducible result, not a one-trial fluke [3]. Honesty about magnitude is part of the record. The effect sizes — an integrated FSFI-desire gain of +0.35 and an FSDS-DAO item-13 reduction of -0.33 — are statistically real but clinically modest, and that is exactly how the regulatory and review literature frames them [3]. Critical re-analyses have argued these effects on desire and distress are small and have questioned the clinical meaningfulness of the chosen outcome measures [3]. An integrated safety analysis across the development program confirmed the tolerability profile, with nausea, flushing, and headache as the leading treatment-emergent events [3]. The benefit is genuine; it is not large. ## The off-label and disputed evidence Outside the approved indication, the evidence thins quickly. The male erectile-dysfunction work was early-phase: dose-ranging studies, including an intranasal route that was later discontinued for inconsistent absorption, showed a dose-dependent erectile response but never produced an approval [1]. A 2008 erectile-dysfunction salvage study (Safarinejad and Hosseini) received a formal Expression of Concern in 2023, so its findings should be treated as disputed and read with caution [3]. Recent preclinical work has also pushed back on simple mechanistic stories. A 2025 study in female Syrian hamsters found that MC3R/MC4R messenger RNA concentrated in ventral-tegmental-area dopamine neurons, yet neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA in the mesolimbic dopamine system, and the drug did not enhance sexual reward in a conditioned-place-preference test — a nuanced, partly negative result suggesting it may not act through the classic reward circuit [3]. A 2025 review situated bremelanotide among current and emerging therapies for premenopausal female sexual dysfunction, keeping it in context as one option rather than a breakthrough [3]. For a structured reading of doses across these programs, see [PT-141 dosage](/dosage); for the off-label male picture in full, see [off-label erectile research](/pt-141-for-men). --- A plain research desktop reading the bremelanotide record straight — the one approved use, the honest tolerability profile, and the off-label evidence kept in its own window; no clinic behind the screen and nothing here dispensed, sourced, or sold.